scholarly journals Effectiveness of Duloxetine Monotherapy Compared to Combination Therapy with Other Antidepressants in Patients with Major Depressive Disorder: A Short-Term, Retrospective Study

2016 ◽  
Vol 13 (4) ◽  
pp. 447
Author(s):  
Eun-Jin Cheon ◽  
Jun-Yeob Lee ◽  
Joong-Hyeon Choi ◽  
Young-Ji Lee ◽  
Bon-Hoon Koo
Keyword(s):  
Major Depressive Disorder ◽  
Retrospective Study ◽  
Combination Therapy ◽  
Depressive Disorder ◽  
Short Term ◽  
Major Depressive

scholarly journals Repeated use of SSRIs potentially associated with an increase on serum CK and CK-MB in patients with major depressive disorder: a retrospective study

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Shengwei Wu ◽  
Yufang Zhou ◽  
Zhengzheng Xuan ◽  
Linghui Xiong ◽  
Xinyu Ge ◽  
...  
Keyword(s):  
Creatine Kinase ◽  
Major Depressive Disorder ◽  
Retrospective Study ◽  
Depressive Disorder ◽  
Selective Serotonin Reuptake Inhibitors ◽  
Cardiac Injury ◽  
First Episode ◽  
Cardiovascular Risks ◽  
Major Depressive ◽  
Depressive Patients

AbstractThere is a large amount of evidence that selective serotonin reuptake inhibitors (SSRIs) are related to cardiovascular toxicity, which has aroused concern regarding their safety. However, few studies have evaluated the effects of SSRIs on cardiac injury biomarkers, such as creatine kinase (CK) and creatine kinase isoenzyme (CK-MB). The purpose of our study was to determine whether SSRIs elevated CK and CK-MB levels of prior medicated depressive patients (PMDP) compared to first-episode drug-naïve depressive patients (FDDPs). We performed an observational and retrospective study involving 128 patients with major depressive disorder. Patients who had never used any type of antidepressant were designated FDDP; patients who had used only one type of SSRI but were not treated after a recent relapse were designated PMDP. Serum CK and CK-MB levels were measured before and after using SSRIs for a period of time. The duration of current treatment in the FDDP and PMDP groups was 16.200 ± 16.726 weeks and 15.618 ± 16.902 weeks, respectively. After SSRI treatment, levels of serum CK in the PMDP group were significantly higher than in the FDDP group. Univariate ANCOVA results revealed that PMDP was 22.313 times more likely to elevate CK (OR 22.313, 95% CI 9.605–35.022) and 2.615 times more likely to elevate CK-MB (OR 2.615, 95% CI 1.287–3.943) than FDDP. Multivariate ANCOVA revealed an interaction between the group and sex of CK and CK-MB. Further pairwise analysis of the interaction results showed that in female patients, the mean difference (MD) of CK and CK-MB in PMDP was significantly greater than that in FDDP (MD = 33.410, P = 0.000, 95% CI 15.935–50.886; MD = 4.613, P = 0.000, 95% CI 2.846–6.381). Our findings suggest that patients, especially females, who had previously used SSRI antidepressants were more likely to have elevated CK and CK-MB, indicators of myocardial muscle injury. Use of SSRIs should not be assumed to be completely safe and without any cardiovascular risks.

Short-term and long-term effects of major depressive disorder subtypes on obesity markers and impact of sex on these associations

2021 ◽  
Author(s):  
Clémentine Ottino ◽  
Marie-Pierre F Strippoli ◽  
Mehdi Gholam ◽  
Aurélie M Lasserre ◽  
Caroline L Vandeleur ◽  
...  
Keyword(s):  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Long Term Effects ◽  
Short Term ◽  
Major Depressive

Augmentation strategies in the treatment of major depressive disorder

2016 ◽  
Vol 33 (S1) ◽  
pp. S407-S407
Author(s):  
S. Bise ◽  
B. Kurtovic ◽  
D. Begic ◽  
O. Cemalovic
Keyword(s):  
Major Depressive Disorder ◽  
Combination Therapy ◽  
Depressive Disorder ◽  
Mood Stabilizers ◽  
Augmentation Therapy ◽  
Major Depressive ◽  
Augmentation Strategies ◽  
Significant Difference ◽  
Augmentation Strategy ◽  
Competing Interest

Augmentation strategies for the treatment of Major depressive disorder (MDD) are needed when patients with MDD have a partial, or not responded to antidepressant monotherapy. The focus of augmentation therapy has been combining an antidepressant (AD) medication with another AD. Atypical antipsychotics (AAP) are becoming commonly used to augment antidepressants. Beyond AD and AAP, alternative augmentation strategies include mood stabilizers (MS).AimTo analyze the characteristics of therapy in patients with diagnosis of MDD and to investigate the frequency of augmentation therapy.MethodStudy included 28 patients hospitalized during one year with MDD diagnosis. Statistical analysis was performed with x2 and t-test.ResultAmong patients with MDD there were 18 (64.28%) women with an average age 57.5 and 10 (35.71%) men with an average age 53.5. Of the 28 patients with MDD, 25 (89.28%) were treated with a combination therapy, and monotherapy in the remaining 3 patients (10.71%). Of 25 patients with augmentation strategy treatment, 22 (88%) used two medications and the remaining 3 (12%) tree psychotropic medications (AAP, AD, MS). The most frequent combinations were a combination of AD and AAP (17 patients, 68%). Beyond that frequent combination were AD and MS (6 patients, 24%). Two patients used combination two AAP, and one patient with two AD and one patients used AAP and MS.ConclusionAugmentation strategy is often used in patients with MDD. There is no significant difference in the use combination therapy based on gender and age.Disclosure of interestThe authors have not supplied their declaration of competing interest.

scholarly journals Predictors of 1-Year Rehospitalization for Patients with Major Depressive Disorder: A Retrospective Study in a University Hospital

2021 ◽  
Vol 19 (2) ◽  
pp. 64-73
Author(s):  
Ji-Min Yoo ◽  
Sung-Min Kim ◽  
Yoo-Hyun Um ◽  
Tae-Won Kim ◽  
Ho-Jun Seo ◽  
...  
Keyword(s):  
Major Depressive Disorder ◽  
Retrospective Study ◽  
Depressive Disorder ◽  
University Hospital ◽  
Major Depressive

Association of Short-term Particulate Matter Exposure with Suicide Death Among Major Depressive Disorder Patients: A Time-Stratified Case-Crossover Analysis

2021 ◽  
Author(s):  
In Young Hwang ◽  
Daein Choi ◽  
Jihoon Andrew Kim ◽  
Seulggie Choi ◽  
Jooyoung Chang ◽  
...  
Keyword(s):  
Major Depressive Disorder ◽  
Particulate Matter ◽  
Depressive Disorder ◽  
Short Term ◽  
Major Depressive ◽  
Suicide Death ◽  
Case Crossover ◽  
Crossover Analysis ◽  
High Level ◽  
Particulate Matter Exposure

Abstract Objective: There is growing evidence that suggests a potential association between particulate matter (PM) and suicide. However, it is unclear that PM exposure and suicide death among major depressive disorder (MDD) patients, a high-risk group for suicide.Methods: We investigated the risk of suicide among 1,046,169 newly-diagnosed MDD patients from 2004 to 2015 within the Korean National Health Insurance Service (NHIS) database. We identified 3,372 suicide cases from January 1, 2015, to December 31, 2017, within the death statistics database of the Korean National Statistical Office. PMs with diameter less than 2.5 μm (PM2.5), less than 10 μm (PM10), and 2.5 μm to 10 μm (PM2.5-10) were considered, which were provided from the National Ambient Air Monitoring System in South Korea. Time-stratified case-crossover analysis was performed to investigate the association of particulate matter exposure to suicide events.Results: The risk of suicide was significantly high upon the high level of exposure to PM2.5-10, PM10 on lag 1 (p for trend = 0.044, 0.035, respectively). A similar association was observed in the multi-day lag model (lag 0-3). Increasing exposure to PM 2.5 was not associated with increased suicide risk.Conclusions: Short-term exposure to a high level of PM2.5-10 and PM10 was associated with an elevated risk for suicide among MDD patients, while PM2.5 did not. There is a clear dose-response relationship between short-term coarse particle exposures with suicide death among Major Depressive Disorder patients. This result will be used as an essential basis for consideration when establishing an air pollution alarm system and implementing a suicide prevention program for reducing adverse health outcomes by PM.

scholarly journals Efficacy of vortioxetine on the physical symptoms of major depressive disorder

2018 ◽  
Vol 32 (10) ◽  
pp. 1086-1097 ◽  
Author(s):  
Michael Cronquist Christensen ◽  
Ioana Florea ◽  
Annika Lindsten ◽  
David S Baldwin
Keyword(s):  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Gastrointestinal Symptoms ◽  
Physical Symptoms ◽  
Anxiety Symptoms ◽  
Hamilton Depression Scale ◽  
Short Term ◽  
Major Depressive ◽  
Symptoms Of Depression ◽  
Long Term Treatment

Background: Efficacy has been proven for vortioxetine in short-term and long-term treatment of major depressive disorder (MDD), with broad beneficial effects on emotional, physical and cognitive symptoms. Limited specific data on the effects of vortioxetine on depression-related physical symptoms have been published. Methods: A meta-analysis was carried out of five short-term multinational, double-blind, placebo-controlled studies. These studies were conducted in a total of 2105 adult MDD outpatients (18–75 years) with a major depressive episode of ⩾3 months’ duration. Only patients treated with a dose of 5 or 10 mg vortioxetine (therapeutic doses) or placebo were included in this analysis. Efficacy assessment of vortioxetine on the physical symptoms of depression included all items of the Hamilton Depression Scale (HAM-D) assessing physical symptoms, and all somatic items in the Hamilton Anxiety Scale (HAM-A). A subgroup analysis in MDD patients with coexisting anxiety symptoms (i.e. those with a HAM-A ⩾20 at baseline) was also performed. Results: A significant improvement ( p<0.05) of vortioxetine versus placebo was observed on all HAM-D items measuring physical symptoms, except for the somatic gastrointestinal symptoms and loss of weight items. Significant effects were also observed on the HAM-A somatic items: general somatic symptoms, gastrointestinal symptoms, and autonomic symptoms. In patients with a high baseline level of anxiety, a significant effect of vortioxetine was also observed on the physical symptoms of depression. Conclusions: These analyses indicate that patients with MDD, including those with a high level of anxiety symptoms, have significant improvements in MDD-associated physical symptoms when treated with vortioxetine.

Sign in / Sign up

Export Citation Format

Share Document